ID   EXO1_HUMAN              Reviewed;         846 AA.
AC   Q9UQ84; O60545; O75214; O75466; Q5T396; Q96IJ1; Q9UG38; Q9UNW0;
DT   24-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 2.
DT   22-JUL-2015, entry version 135.
DE   RecName: Full=Exonuclease 1;
DE            Short=hExo1;
DE            EC=3.1.-.-;
DE   AltName: Full=Exonuclease I;
DE            Short=hExoI;
GN   Name=EXO1; Synonyms=EXOI, HEX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH MSH2, TISSUE
RP   SPECIFICITY, AND VARIANTS ARG-354; LYS-589; GLY-670; CYS-723 AND
RP   LEU-757.
RX   PubMed=9788596;
RA   Schmutte C., Marinescu R.C., Sadoff M.M., Guerrette S., Overhauser J.,
RA   Fishel R.;
RT   "Human exonuclease I interacts with the mismatch repair protein
RT   hMSH2.";
RL   Cancer Res. 58:4537-4542(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, TISSUE
RP   SPECIFICITY, AND VARIANTS ARG-354; LYS-589; GLY-670 AND CYS-723.
RX   PubMed=9823303;
RA   Tishkoff D.X., Amin N.S., Viars C.S., Arden K.C., Kolodner R.D.;
RT   "Identification of a human gene encoding a homologue of Saccharomyces
RT   cerevisiae EXO1, an exonuclease implicated in mismatch repair and
RT   recombination.";
RL   Cancer Res. 58:5027-5031(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING,
RP   FUNCTION, TISSUE SPECIFICITY, AND VARIANTS ARG-354; LYS-589; GLY-670
RP   AND CYS-723.
RC   TISSUE=Sperm;
RX   PubMed=9685493; DOI=10.1093/nar/26.16.3762;
RA   Wilson D.M. III, Carney J.P., Coleman M.A., Adamson A.W.,
RA   Christensen M., Lamerdin J.E.;
RT   "Hex1: a new human Rad2 nuclease family member with homology to yeast
RT   exonuclease 1.";
RL   Nucleic Acids Res. 26:3762-3768(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF 1-7
RP   (ISOFORMS 1/2), FUNCTION, AND VARIANTS ARG-354; LYS-589; GLY-670 AND
RP   CYS-723.
RX   PubMed=10364235; DOI=10.1074/jbc.274.25.17893;
RA   Qiu J., Qian Y., Chen V., Guan M.-X., Shen B.;
RT   "Human exonuclease 1 functionally complements its yeast homologues in
RT   DNA recombination, RNA primer removal, and mutation avoidance.";
RL   J. Biol. Chem. 274:17893-17900(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-76; GLY-93;
RP   SER-279; SER-299; ARG-354; ASN-428; MET-439; TYR-456; MET-458;
RP   LEU-460; THR-503; LYS-589; GLN-634; GLY-670; CYS-723; LEU-757 AND
RP   GLU-759.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLY-670 AND CYS-723.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 175-846 (ISOFORM 1), AND
RP   VARIANTS LYS-589; GLY-670 AND CYS-723.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   FUNCTION.
RX   PubMed=10608837; DOI=10.1074/jbc.274.53.37763;
RA   Lee B.-I., Wilson D.M. III;
RT   "The RAD2 domain of human exonuclease 1 exhibits 5' to 3' exonuclease
RT   and flap structure-specific endonuclease activities.";
RL   J. Biol. Chem. 274:37763-37769(1999).
RN   [10]
RP   INTERACTION WITH MSH2, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=10856833; DOI=10.1016/S0921-8777(00)00012-4;
RA   Rasmussen L.J., Rasmussen M., Lee B.-I., Rasmussen A.K.,
RA   Wilson D.M. III, Nielsen F.C., Bisgaard H.C.;
RT   "Identification of factors interacting with hMSH2 in the fetal liver
RT   utilizing the yeast two-hybrid system. In vivo interaction through the
RT   C-terminal domains of hEXO1 and hMSH2 and comparative expression
RT   analysis.";
RL   Mutat. Res. 460:41-52(2000).
RN   [11]
RP   INTERACTION WITH MLH1; MSH2 AND MSH3.
RX   PubMed=11427529; DOI=10.1074/jbc.M102670200;
RA   Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.;
RT   "The interaction of DNA mismatch repair proteins with human
RT   exonuclease I.";
RL   J. Biol. Chem. 276:33011-33018(2001).
RN   [12]
RP   INTERACTION WITH MLH1 AND MSH2, AND SUBCELLULAR LOCATION.
RX   PubMed=11429708; DOI=10.1038/sj.onc.1204467;
RA   Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C.,
RA   Rasmussen L.J.;
RT   "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence
RT   assembly of hMutLalpha and hMLH1-hEXO1 complexes.";
RL   Oncogene 20:3590-3595(2001).
RN   [13]
RP   FUNCTION, INTERACTION WITH MLH1 AND MSH2, AND CHARACTERIZATION OF
RP   VARIANTS LYS-109; ARG-410; SER-640; GLU-759 AND LEU-770.
RX   PubMed=12414623;
RA   Sun X., Zheng L., Shen B.;
RT   "Functional alterations of human exonuclease 1 mutants identified in
RT   atypical hereditary nonpolyposis colorectal cancer syndrome.";
RL   Cancer Res. 62:6026-6030(2002).
RN   [14]
RP   FUNCTION.
RX   PubMed=11809771; DOI=10.1074/jbc.M111854200;
RA   Genschel J., Bazemore L.R., Modrich P.;
RT   "Human exonuclease I is required for 5' and 3' mismatch repair.";
RL   J. Biol. Chem. 277:13302-13311(2002).
RN   [15]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF ASP-78; ASP-173 AND ASP-225.
RX   PubMed=11842105; DOI=10.1093/nar/30.4.942;
RA   Lee B.-I., Nguyen L.H., Barsky D., Fernandes M., Wilson D.M. III;
RT   "Molecular interactions of human Exo1 with DNA.";
RL   Nucleic Acids Res. 30:942-949(2002).
RN   [16]
RP   INVOLVEMENT IN COLORECTAL CANCER.
RX   PubMed=14623461; DOI=10.1016/S0165-4608(03)00196-1;
RA   Alam N.A., Gorman P., Jaeger E.E.M., Kelsell D., Leigh I.M.,
RA   Ratnavel R., Murdoch M.E., Houlston R.S., Aaltonen L.A.,
RA   Roylance R.R., Tomlinson I.P.M.;
RT   "Germline deletions of EXO1 do not cause colorectal tumors and lesions
RT   which are null for EXO1 do not have microsatellite instability.";
RL   Cancer Genet. Cytogenet. 147:121-127(2003).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH WRN.
RX   PubMed=12704184; DOI=10.1074/jbc.M212798200;
RA   Sharma S., Sommers J.A., Driscoll H.C., Uzdilla L.A., Wilson T.M.,
RA   Brosh R.M. Jr.;
RT   "The exonucleolytic and endonucleolytic cleavage activities of human
RT   exonuclease 1 are stimulated by an interaction with the carboxyl-
RT   terminal region of the Werner syndrome protein.";
RL   J. Biol. Chem. 278:23487-23496(2003).
RN   [18]
RP   FUNCTION.
RX   PubMed=14636568; DOI=10.1016/S1097-2765(03)00428-3;
RA   Genschel J., Modrich P.;
RT   "Mechanism of 5'-directed excision in human mismatch repair.";
RL   Mol. Cell 12:1077-1086(2003).
RN   [19]
RP   FUNCTION, INTERACTION WITH PCNA, AND MUTAGENESIS OF ASP-173.
RX   PubMed=15225546; DOI=10.1016/j.molcel.2004.06.016;
RA   Dzantiev L., Constantin N., Genschel J., Iyer R.R., Burgers P.M.,
RA   Modrich P.;
RT   "A defined human system that supports bidirectional mismatch-provoked
RT   excision.";
RL   Mol. Cell 15:31-41(2004).
RN   [20]
RP   FUNCTION, INTERACTION WITH MLH1 AND MSH2, AND SUBCELLULAR LOCATION.
RX   PubMed=14676842; DOI=10.1038/sj.onc.1207265;
RA   Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.;
RT   "Characterization of human exonuclease 1 in complex with mismatch
RT   repair proteins, subcellular localization and association with PCNA.";
RL   Oncogene 23:1457-1468(2004).
RN   [21]
RP   FUNCTION.
RX   PubMed=16143102; DOI=10.1016/j.cell.2005.06.027;
RA   Zhang Y., Yuan F., Presnell S.R., Tian K., Gao Y., Tomkinson A.E.,
RA   Gu L., Li G.-M.;
RT   "Reconstitution of 5'-directed human mismatch repair in a purified
RT   system.";
RL   Cell 122:693-705(2005).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH RECQL.
RX   PubMed=15886194; DOI=10.1074/jbc.M500265200;
RA   Doherty K.M., Sharma S., Uzdilla L.A., Wilson T.M., Cui S.,
RA   Vindigni A., Brosh R.M. Jr.;
RT   "RECQ1 helicase interacts with human mismatch repair factors that
RT   regulate genetic recombination.";
RL   J. Biol. Chem. 280:28085-28094(2005).
RN   [23]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-418 AND ARG-419.
RX   PubMed=17426132; DOI=10.1093/nar/gkl1166;
RA   Knudsen N.O., Nielsen F.C., Vinther L., Bertelsen R.,
RA   Holten-Andersen S., Liberti S.E., Hofstra R., Kooi K., Rasmussen L.J.;
RT   "Nuclear localization of human DNA mismatch repair protein exonuclease
RT   1 (hEXO1).";
RL   Nucleic Acids Res. 35:2609-2619(2007).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [25]
RP   PHOSPHORYLATION AT SER-376; SER-422; SER-454; THR-581; SER-598;
RP   THR-621; SER-623; SER-639; SER-660; SER-674; SER-714 AND SER-746,
RP   ACETYLATION AT LYS-482, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   MUTAGENESIS OF SER-454; THR-621 AND SER-714.
RX   PubMed=18048416; DOI=10.1093/nar/gkm1052;
RA   El-Shemerly M., Hess D., Pyakurel A.K., Moselhy S., Ferrari S.;
RT   "ATR-dependent pathways control hEXO1 stability in response to stalled
RT   forks.";
RL   Nucleic Acids Res. 36:511-519(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-422, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   VARIANTS ALA-27; LYS-109; ARG-410; GLY-610; ALA-640; SER-640; GLU-759
RP   AND LEU-770.
RX   PubMed=11375940; DOI=10.1053/gast.2001.25117;
RA   Wu Y., Berends M.J.W., Post J.G., Mensink R.G.J., Verlind E.,
RA   van der Sluis T., Kempinga C., Sijmons R.H., van der Zee A.G.J.,
RA   Hollema H., Kleibeuker J.H., Buys C.H.C.M., Hofstra R.M.W.;
RT   "Germline mutations of EXO1 gene in patients with hereditary
RT   nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms.";
RL   Gastroenterology 120:1580-1587(2001).
RN   [29]
RP   VARIANTS SER-137; ARG-410; CYS-438; GLY-610; ALA-640; SER-640; GLU-759
RP   AND VAL-827.
RX   PubMed=12517792;
RA   Jagmohan-Changur S., Poikonen T., Vilkki S., Launonen V., Wikman F.,
RA   Orntoft T.F., Moeller P., Vasen H., Tops C., Kolodner R.D.,
RA   Mecklin J.-P., Jaervinen H., Bevan S., Houlston R.S., Aaltonen L.A.,
RA   Fodde R., Wijnen J., Karhu A.;
RT   "EXO1 variants occur commonly in normal population: evidence against a
RT   role in hereditary nonpolyposis colorectal cancer.";
RL   Cancer Res. 63:154-158(2003).
RN   [30]
RP   VARIANTS MET-439; GLY-670; PRO-726 AND LEU-757.
RX   PubMed=14756672; DOI=10.1111/j.1399-0004.2004.00214.x;
RA   Thompson E., Meldrum C.J., Crooks R., McPhillips M., Thomas L.,
RA   Spigelman A.D., Scott R.J.;
RT   "Hereditary non-polyposis colorectal cancer and the role of hPMS2 and
RT   hEXO1 mutations.";
RL   Clin. Genet. 65:215-225(2004).
RN   [31]
RP   VARIANTS MET-439 AND LEU-757.
RX   PubMed=15550454; DOI=10.1093/carcin/bgh335;
RA   Yamamoto H., Hanafusa H., Ouchida M., Yano M., Suzuki H., Murakami M.,
RA   Aoe M., Shimizu N., Nakachi K., Shimizu K.;
RT   "Single nucleotide polymorphisms in the EXO1 gene and risk of
RT   colorectal cancer in a Japanese population.";
RL   Carcinogenesis 26:411-416(2005).
CC   -!- FUNCTION: 5'->3' double-stranded DNA exonuclease which may also
CC       possess a cryptic 3'->5' double-stranded DNA exonuclease activity.
CC       Functions in DNA mismatch repair (MMR) to excise mismatch-
CC       containing DNA tracts directed by strand breaks located either 5'
CC       or 3' to the mismatch. Also exhibits endonuclease activity against
CC       5'-overhanging flap structures similar to those generated by
CC       displacement synthesis when DNA polymerase encounters the 5'-end
CC       of a downstream Okazaki fragment. Required for somatic
CC       hypermutation (SHM) and class switch recombination (CSR) of
CC       immunoglobulin genes. Essential for male and female meiosis.
CC       {ECO:0000269|PubMed:10364235, ECO:0000269|PubMed:10608837,
CC       ECO:0000269|PubMed:11809771, ECO:0000269|PubMed:11842105,
CC       ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:12704184,
CC       ECO:0000269|PubMed:14636568, ECO:0000269|PubMed:14676842,
CC       ECO:0000269|PubMed:15225546, ECO:0000269|PubMed:15886194,
CC       ECO:0000269|PubMed:16143102, ECO:0000269|PubMed:9685493}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions per subunit. They probably participate
CC       in the reaction catalyzed by the enzyme. May bind an additional
CC       third magnesium ion after substrate binding. {ECO:0000250};
CC   -!- SUBUNIT: Interacts with the MLH1-PMS2 heterodimer via MLH1.
CC       Interacts with MSH3. Interacts with the MSH2-MSH6 heterodimer via
CC       MSH2, and this interaction may increase the processivity of the
CC       5'->3' exonuclease activity. Interacts with PCNA, and this
CC       interaction may both stimulate the cryptic 3'->5' exonuclease
CC       activity and suppress the 5'->3' exonuclease activity. Interacts
CC       with WRN, and this interaction stimulates both the 5'->3'
CC       exonuclease activity and cleavage of 5'-overhanging flap
CC       structures. Interacts with RECQL/RECQ1, and this interaction
CC       stimulates cleavage of 5'-overhanging flap structures.
CC       {ECO:0000269|PubMed:10856833, ECO:0000269|PubMed:11427529,
CC       ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623,
CC       ECO:0000269|PubMed:12704184, ECO:0000269|PubMed:14676842,
CC       ECO:0000269|PubMed:15225546, ECO:0000269|PubMed:15886194,
CC       ECO:0000269|PubMed:9788596}.
CC   -!- INTERACTION:
CC       P43246:MSH2; NbExp=3; IntAct=EBI-944694, EBI-355888;
CC       Q99708:RBBP8; NbExp=3; IntAct=EBI-944667, EBI-745715;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708,
CC       ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:17426132}.
CC       Note=Colocalizes with PCNA to discrete nuclear foci in S-phase.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=B;
CC         IsoId=Q9UQ84-1; Sequence=Displayed;
CC       Name=2; Synonyms=A;
CC         IsoId=Q9UQ84-4; Sequence=VSP_017029, VSP_017030;
CC   -!- TISSUE SPECIFICITY: Highly expressed in bone marrow, testis and
CC       thymus. Expressed at lower levels in colon, lymph nodes, ovary,
CC       placenta, prostate, small intestine, spleen and stomach.
CC       {ECO:0000269|PubMed:10856833, ECO:0000269|PubMed:9685493,
CC       ECO:0000269|PubMed:9788596, ECO:0000269|PubMed:9823303}.
CC   -!- DEVELOPMENTAL STAGE: Highly expressed in fetal liver and at lower
CC       levels in fetal brain, heart, kidney, spleen and thymus.
CC       {ECO:0000269|PubMed:10856833}.
CC   -!- PTM: Phosphorylated upon DNA damage and in response to agents
CC       stalling DNA replication, probably by ATM or ATR. Phosphorylation
CC       at Ser-454, Thr-621 and Ser-714 is induced upon DNA-damage caused
CC       by treatment with hydroxyurea (HU) but not upon IR treatment. The
CC       HU-induced EXO1 triple phosphorylation facilitates
CC       destabilisation/degradation of the protein.
CC       {ECO:0000269|PubMed:18048416}.
CC   -!- POLYMORPHISM: Most naturally occurring variants in this protein
CC       are not associated with familial disposition to hereditary non-
CC       polyposis colorectal cancer (HNPCC). Furthermore, germline
CC       deletions involving this locus are not associated with clinically
CC       manifested colorectal tumors.
CC   -!- SIMILARITY: Belongs to the XPG/RAD2 endonuclease family. EXO1
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC33874.1; Type=Frameshift; Positions=793; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/exo1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF084974; AAD13754.1; -; mRNA.
DR   EMBL; AF091740; AAC63043.1; -; mRNA.
DR   EMBL; AF091754; AAC69879.1; -; Genomic_DNA.
DR   EMBL; AF091742; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091743; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091744; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091745; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091746; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091747; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091748; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091749; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091750; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091751; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091752; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091753; AAC69879.1; JOINED; Genomic_DNA.
DR   EMBL; AF091754; AAC69880.1; -; Genomic_DNA.
DR   EMBL; AF091742; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091743; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091744; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091745; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091746; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091747; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091748; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091749; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091750; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091751; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091752; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF091753; AAC69880.1; JOINED; Genomic_DNA.
DR   EMBL; AF042282; AAC32259.1; -; mRNA.
DR   EMBL; AC004783; AAC32424.1; -; Genomic_DNA.
DR   EMBL; AF060479; AAC33874.1; ALT_FRAME; mRNA.
DR   EMBL; AF549168; AAN39382.1; -; Genomic_DNA.
DR   EMBL; AL365366; CAI15658.1; -; Genomic_DNA.
DR   EMBL; BC007491; AAH07491.1; -; mRNA.
DR   EMBL; AL080139; CAB45733.1; -; mRNA.
DR   CCDS; CCDS1620.1; -. [Q9UQ84-1]
DR   CCDS; CCDS44336.1; -. [Q9UQ84-4]
DR   PIR; T12524; T12524.
DR   RefSeq; NP_003677.4; NM_003686.4. [Q9UQ84-4]
DR   RefSeq; NP_006018.4; NM_006027.4. [Q9UQ84-1]
DR   RefSeq; NP_569082.2; NM_130398.3. [Q9UQ84-1]
DR   RefSeq; XP_006711903.1; XM_006711840.1. [Q9UQ84-1]
DR   RefSeq; XP_011542623.1; XM_011544321.1. [Q9UQ84-1]
DR   RefSeq; XP_011542624.1; XM_011544322.1. [Q9UQ84-1]
DR   UniGene; Hs.498248; -.
DR   PDB; 3QE9; X-ray; 2.51 A; Y/Z=1-352.
DR   PDB; 3QEA; X-ray; 3.10 A; Z=1-352.
DR   PDB; 3QEB; X-ray; 3.00 A; Z=1-352.
DR   PDBsum; 3QE9; -.
DR   PDBsum; 3QEA; -.
DR   PDBsum; 3QEB; -.
DR   ProteinModelPortal; Q9UQ84; -.
DR   SMR; Q9UQ84; 2-346.
DR   BioGrid; 114602; 18.
DR   DIP; DIP-36701N; -.
DR   IntAct; Q9UQ84; 7.
DR   MINT; MINT-84735; -.
DR   STRING; 9606.ENSP00000311873; -.
DR   PhosphoSite; Q9UQ84; -.
DR   BioMuta; EXO1; -.
DR   DMDM; 85700954; -.
DR   MaxQB; Q9UQ84; -.
DR   PaxDb; Q9UQ84; -.
DR   PRIDE; Q9UQ84; -.
DR   DNASU; 9156; -.
DR   Ensembl; ENST00000348581; ENSP00000311873; ENSG00000174371.
DR   Ensembl; ENST00000366548; ENSP00000355506; ENSG00000174371.
DR   Ensembl; ENST00000518483; ENSP00000430251; ENSG00000174371. [Q9UQ84-4]
DR   GeneID; 9156; -.
DR   KEGG; hsa:9156; -.
DR   UCSC; uc001hzh.3; human. [Q9UQ84-1]
DR   UCSC; uc021plk.1; human. [Q9UQ84-4]
DR   CTD; 9156; -.
DR   GeneCards; GC01P242011; -.
DR   H-InvDB; HIX0022634; -.
DR   HGNC; HGNC:3511; EXO1.
DR   MIM; 606063; gene.
DR   neXtProt; NX_Q9UQ84; -.
DR   PharmGKB; PA27923; -.
DR   eggNOG; COG0258; -.
DR   GeneTree; ENSGT00510000047676; -.
DR   HOVERGEN; HBG081488; -.
DR   InParanoid; Q9UQ84; -.
DR   KO; K10746; -.
DR   OMA; EPIHVRK; -.
DR   OrthoDB; EOG7RNJZZ; -.
DR   PhylomeDB; Q9UQ84; -.
DR   TreeFam; TF314997; -.
DR   BRENDA; 3.1.11.1; 2681.
DR   Reactome; REACT_264347; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta).
DR   Reactome; REACT_264501; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha).
DR   EvolutionaryTrace; Q9UQ84; -.
DR   GeneWiki; Exonuclease_1; -.
DR   GenomeRNAi; 9156; -.
DR   NextBio; 34349; -.
DR   PRO; PR:Q9UQ84; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q9UQ84; -.
DR   CleanEx; HS_EXO1; -.
DR   ExpressionAtlas; Q9UQ84; baseline and differential.
DR   Genevisible; Q9UQ84; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035312; F:5'-3' exodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0008409; F:5'-3' exonuclease activity; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0051908; F:double-stranded DNA 5'-3' exodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0004527; F:exonuclease activity; TAS:ProtInc.
DR   GO; GO:0048256; F:flap endonuclease activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; TAS:ProtInc.
DR   GO; GO:0045145; F:single-stranded DNA 5'-3' exodeoxyribonuclease activity; IDA:UniProtKB.
DR   GO; GO:0043566; F:structure-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0006310; P:DNA recombination; IGI:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:Reactome.
DR   GO; GO:0002455; P:humoral immune response mediated by circulating immunoglobulin; IEA:Ensembl.
DR   GO; GO:0045190; P:isotype switching; IEA:Ensembl.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006298; P:mismatch repair; IDA:UniProtKB.
DR   GO; GO:0090305; P:nucleic acid phosphodiester bond hydrolysis; IDA:GOC.
DR   GO; GO:0090502; P:RNA phosphodiester bond hydrolysis, endonucleolytic; TAS:GOC.
DR   GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IEA:Ensembl.
DR   Gene3D; 3.40.50.1010; -; 1.
DR   InterPro; IPR020045; 5-3_exonuclease_C.
DR   InterPro; IPR008918; HhH2.
DR   InterPro; IPR029060; PIN_domain-like.
DR   InterPro; IPR006086; XPG-I_dom.
DR   InterPro; IPR006084; XPG/Rad2.
DR   InterPro; IPR019974; XPG_CS.
DR   InterPro; IPR006085; XPG_DNA_repair_N.
DR   PANTHER; PTHR11081; PTHR11081; 1.
DR   Pfam; PF00867; XPG_I; 1.
DR   Pfam; PF00752; XPG_N; 1.
DR   PRINTS; PR00853; XPGRADSUPER.
DR   SMART; SM00279; HhH2; 1.
DR   SMART; SM00484; XPGI; 1.
DR   SMART; SM00485; XPGN; 1.
DR   SUPFAM; SSF47807; SSF47807; 1.
DR   SUPFAM; SSF88723; SSF88723; 1.
DR   PROSITE; PS00841; XPG_1; 1.
DR   PROSITE; PS00842; XPG_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; DNA damage; DNA excision; DNA repair;
KW   DNA-binding; Endonuclease; Excision nuclease; Exonuclease; Hydrolase;
KW   Immunity; Magnesium; Meiosis; Metal-binding; Nuclease; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    846       Exonuclease 1.
FT                                /FTId=PRO_0000154039.
FT   REGION        1     99       N-domain.
FT   REGION      129    387       Interaction with MSH3.
FT   REGION      138    229       I-domain.
FT   REGION      388    490       Interaction with MLH1.
FT   REGION      600    846       Interaction with MSH2.
FT   REGION      787    846       Interaction with MLH1.
FT   MOTIF       418    421       Nuclear localization signal.
FT   METAL        30     30       Magnesium 1. {ECO:0000250}.
FT   METAL        78     78       Magnesium 1. {ECO:0000250}.
FT   METAL       150    150       Magnesium 1. {ECO:0000250}.
FT   METAL       152    152       Magnesium 1. {ECO:0000250}.
FT   METAL       171    171       Magnesium 2. {ECO:0000250}.
FT   METAL       173    173       Magnesium 2. {ECO:0000250}.
FT   METAL       225    225       Magnesium 2. {ECO:0000250}.
FT   MOD_RES     376    376       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     422    422       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416,
FT                                ECO:0000269|PubMed:18669648}.
FT   MOD_RES     454    454       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     482    482       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     581    581       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     598    598       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     621    621       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     623    623       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     639    639       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     660    660       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     674    674       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     714    714       Phosphoserine; by ATR.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MOD_RES     746    746       Phosphoserine.
FT                                {ECO:0000269|PubMed:18048416}.
FT   VAR_SEQ     803    803       D -> F (in isoform 2).
FT                                {ECO:0000303|PubMed:10364235}.
FT                                /FTId=VSP_017029.
FT   VAR_SEQ     804    846       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10364235}.
FT                                /FTId=VSP_017030.
FT   VARIANT      27     27       V -> A. {ECO:0000269|PubMed:11375940}.
FT                                /FTId=VAR_024966.
FT   VARIANT      76     76       V -> I (in dbSNP:rs4149864).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024967.
FT   VARIANT      93     93       R -> G (in dbSNP:rs4149865).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024968.
FT   VARIANT     109    109       E -> K (abrogates exonuclease activity).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12414623}.
FT                                /FTId=VAR_024969.
FT   VARIANT     137    137       A -> S. {ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024970.
FT   VARIANT     279    279       N -> S (in dbSNP:rs4149909).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024971.
FT   VARIANT     299    299       N -> S (in dbSNP:rs4149910).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024972.
FT   VARIANT     354    354       H -> R (in dbSNP:rs735943).
FT                                {ECO:0000269|PubMed:10364235,
FT                                ECO:0000269|PubMed:9685493,
FT                                ECO:0000269|PubMed:9788596,
FT                                ECO:0000269|PubMed:9823303,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024973.
FT   VARIANT     410    410       L -> R (abrogates exonuclease activity).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12414623,
FT                                ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024974.
FT   VARIANT     428    428       D -> N (in dbSNP:rs4149962).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024975.
FT   VARIANT     438    438       F -> C. {ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024976.
FT   VARIANT     439    439       T -> M (may be associated with an
FT                                increased risk of colorectal cancer;
FT                                dbSNP:rs4149963).
FT                                {ECO:0000269|PubMed:14756672,
FT                                ECO:0000269|PubMed:15550454,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024977.
FT   VARIANT     456    456       S -> Y (in dbSNP:rs4149964).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024978.
FT   VARIANT     458    458       V -> M (in dbSNP:rs4149965).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024979.
FT   VARIANT     460    460       V -> L (in dbSNP:rs4149966).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024980.
FT   VARIANT     503    503       R -> T (in dbSNP:rs4149967).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024981.
FT   VARIANT     589    589       E -> K (in dbSNP:rs1047840).
FT                                {ECO:0000269|PubMed:10364235,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:9685493,
FT                                ECO:0000269|PubMed:9788596,
FT                                ECO:0000269|PubMed:9823303,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024982.
FT   VARIANT     610    610       S -> G (in dbSNP:rs12122770).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024983.
FT   VARIANT     634    634       R -> Q (in dbSNP:rs4149978).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024984.
FT   VARIANT     640    640       P -> A (in dbSNP:rs61736331).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024985.
FT   VARIANT     640    640       P -> S (reduces interaction with MSH2;
FT                                abrogates interaction with MSH2; when
FT                                associated with L-770; dbSNP:rs61736331).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12414623,
FT                                ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024986.
FT   VARIANT     670    670       E -> G (in dbSNP:rs1776148).
FT                                {ECO:0000269|PubMed:10364235,
FT                                ECO:0000269|PubMed:14756672,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:9685493,
FT                                ECO:0000269|PubMed:9788596,
FT                                ECO:0000269|PubMed:9823303,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024987.
FT   VARIANT     723    723       R -> C (in dbSNP:rs1635498).
FT                                {ECO:0000269|PubMed:10364235,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:9685493,
FT                                ECO:0000269|PubMed:9788596,
FT                                ECO:0000269|PubMed:9823303,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024988.
FT   VARIANT     726    726       H -> P. {ECO:0000269|PubMed:14756672}.
FT                                /FTId=VAR_024989.
FT   VARIANT     757    757       P -> L (may be associated with a reduced
FT                                risk of colorectal cancer; dbSNP:rs9350).
FT                                {ECO:0000269|PubMed:14756672,
FT                                ECO:0000269|PubMed:15550454,
FT                                ECO:0000269|PubMed:9788596,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024990.
FT   VARIANT     759    759       G -> E (reduces interaction with MSH2;
FT                                abrogates interaction with MSH2; when
FT                                associated with L-770; dbSNP:rs4150001).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12414623,
FT                                ECO:0000269|PubMed:12517792,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_024991.
FT   VARIANT     770    770       P -> L (reduces interaction with MSH2;
FT                                abrogates interaction with MSH2; when
FT                                associated with S-640 or E-759).
FT                                {ECO:0000269|PubMed:11375940,
FT                                ECO:0000269|PubMed:12414623}.
FT                                /FTId=VAR_024992.
FT   VARIANT     827    827       A -> V. {ECO:0000269|PubMed:12517792}.
FT                                /FTId=VAR_024993.
FT   MUTAGEN      78     78       D->A: Abrogates double-stranded DNA
FT                                exonuclease activity and endonuclease
FT                                activity against 5'-overhanging flap
FT                                structures. Also reduces DNA-binding to
FT                                5'-overhanging flap structures.
FT                                {ECO:0000269|PubMed:11842105}.
FT   MUTAGEN     173    173       D->A: Abrogates double-stranded DNA
FT                                exonuclease activity and endonuclease
FT                                activity against 5'-overhanging flap
FT                                structures. No effect on DNA-binding to
FT                                5'-overhanging flap structures.
FT                                {ECO:0000269|PubMed:11842105,
FT                                ECO:0000269|PubMed:15225546}.
FT   MUTAGEN     225    225       D->A: Abrogates double-stranded DNA
FT                                exonuclease activity and endonuclease
FT                                activity against 5'-overhanging flap
FT                                structures. Also enhances DNA-binding to
FT                                5'-overhanging flap structures.
FT                                {ECO:0000269|PubMed:11842105}.
FT   MUTAGEN     418    418       K->A,T: Complete loss of nuclear
FT                                localization.
FT                                {ECO:0000269|PubMed:17426132}.
FT   MUTAGEN     419    419       R->A: Complete loss of nuclear
FT                                localization.
FT                                {ECO:0000269|PubMed:17426132}.
FT   MUTAGEN     454    454       S->A: No rescue of HU-induced
FT                                degradation. No rescue of HU-induced
FT                                degradation; when associated with A-714.
FT                                Loss of HU-sensitivity and resistance to
FT                                HU-induced degradation; when associated
FT                                with A-621 and A-714.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MUTAGEN     621    621       T->A: No rescue of HU-induced
FT                                degradation. No rescue of HU-induced
FT                                degradation; when associated with A-714.
FT                                Loss of HU-sensitivity and resistance to
FT                                HU-induced degradation; when associated
FT                                with A-454 and A-714.
FT                                {ECO:0000269|PubMed:18048416}.
FT   MUTAGEN     714    714       S->A: No rescue of HU-induced degradation
FT                                and loss of HU-induced increase of
FT                                phosphorylation. No rescue of HU-induced
FT                                degradation; when associated with A-621.
FT                                No rescue of HU-induced degradation; when
FT                                associated with A-454. Loss of HU-
FT                                sensitivity and resistance to HU-induced
FT                                degradation; when associated with A-454
FT                                and A-621. {ECO:0000269|PubMed:18048416}.
FT   HELIX         6      9       {ECO:0000244|PDB:3QE9}.
FT   TURN         10     12       {ECO:0000244|PDB:3QE9}.
FT   STRAND       13     18       {ECO:0000244|PDB:3QE9}.
FT   HELIX        19     22       {ECO:0000244|PDB:3QE9}.
FT   STRAND       25     30       {ECO:0000244|PDB:3QE9}.
FT   HELIX        32     41       {ECO:0000244|PDB:3QE9}.
FT   HELIX        43     47       {ECO:0000244|PDB:3QE9}.
FT   HELIX        54     68       {ECO:0000244|PDB:3QE9}.
FT   STRAND       72     77       {ECO:0000244|PDB:3QE9}.
FT   TURN         83     85       {ECO:0000244|PDB:3QE9}.
FT   HELIX        86    106       {ECO:0000244|PDB:3QE9}.
FT   TURN        107    109       {ECO:0000244|PDB:3QEA}.
FT   HELIX       113    119       {ECO:0000244|PDB:3QE9}.
FT   HELIX       120    122       {ECO:0000244|PDB:3QE9}.
FT   HELIX       127    139       {ECO:0000244|PDB:3QE9}.
FT   STRAND      143    146       {ECO:0000244|PDB:3QE9}.
FT   HELIX       151    160       {ECO:0000244|PDB:3QE9}.
FT   STRAND      165    168       {ECO:0000244|PDB:3QE9}.
FT   HELIX       172    177       {ECO:0000244|PDB:3QE9}.
FT   STRAND      180    185       {ECO:0000244|PDB:3QE9}.
FT   STRAND      190    196       {ECO:0000244|PDB:3QE9}.
FT   HELIX       197    200       {ECO:0000244|PDB:3QE9}.
FT   TURN        204    208       {ECO:0000244|PDB:3QEB}.
FT   HELIX       212    222       {ECO:0000244|PDB:3QE9}.
FT   STRAND      225    227       {ECO:0000244|PDB:3QE9}.
FT   HELIX       235    244       {ECO:0000244|PDB:3QE9}.
FT   HELIX       250    254       {ECO:0000244|PDB:3QE9}.
FT   HELIX       257    261       {ECO:0000244|PDB:3QE9}.
FT   HELIX       269    284       {ECO:0000244|PDB:3QE9}.
FT   STRAND      286    289       {ECO:0000244|PDB:3QE9}.
FT   TURN        290    293       {ECO:0000244|PDB:3QE9}.
FT   STRAND      294    299       {ECO:0000244|PDB:3QE9}.
FT   HELIX       307    309       {ECO:0000244|PDB:3QE9}.
FT   HELIX       311    313       {ECO:0000244|PDB:3QEB}.
FT   HELIX       319    326       {ECO:0000244|PDB:3QE9}.
FT   TURN        332    334       {ECO:0000244|PDB:3QE9}.
SQ   SEQUENCE   846 AA;  94103 MW;  850BC21CA9790D08 CRC64;
     MGIQGLLQFI KEASEPIHVR KYKGQVVAVD TYCWLHKGAI ACAEKLAKGE PTDRYVGFCM
     KFVNMLLSHG IKPILVFDGC TLPSKKEVER SRRERRQANL LKGKQLLREG KVSEARECFT
     RSINITHAMA HKVIKAARSQ GVDCLVAPYE ADAQLAYLNK AGIVQAIITE DSDLLAFGCK
     KVILKMDQFG NGLEIDQARL GMCRQLGDVF TEEKFRYMCI LSGCDYLSSL RGIGLAKACK
     VLRLANNPDI VKVIKKIGHY LKMNITVPED YINGFIRANN TFLYQLVFDP IKRKLIPLNA
     YEDDVDPETL SYAGQYVDDS IALQIALGNK DINTFEQIDD YNPDTAMPAH SRSHSWDDKT
     CQKSANVSSI WHRNYSPRPE SGTVSDAPQL KENPSTVGVE RVISTKGLNL PRKSSIVKRP
     RSAELSEDDL LSQYSLSFTK KTKKNSSEGN KSLSFSEVFV PDLVNGPTNK KSVSTPPRTR
     NKFATFLQRK NEESGAVVVP GTRSRFFCSS DSTDCVSNKV SIQPLDETAV TDKENNLHES
     EYGDQEGKRL VDTDVARNSS DDIPNNHIPG DHIPDKATVF TDEESYSFES SKFTRTISPP
     TLGTLRSCFS WSGGLGDFSR TPSPSPSTAL QQFRRKSDSP TSLPENNMSD VSQLKSEESS
     DDESHPLREE ACSSQSQESG EFSLQSSNAS KLSQCSSKDS DSEESDCNIK LLDSQSDQTS
     KLRLSHFSKK DTPLRNKVPG LYKSSSADSL STTKIKPLGP ARASGLSKKP ASIQKRKHHN
     AENKPGLQIK LNELWKNFGF KKDSEKLPPC KKPLSPVRDN IQLTPEAEED IFNKPECGRV
     QRAIFQ
//
